Enhancing risk stratification in diabetic gastric cancer: muscle-fat ratio from photon-counting CT as a predictor of postoperative complications
- PMID: 40830775
- PMCID: PMC12363078
- DOI: 10.1186/s12880-025-01872-1
Enhancing risk stratification in diabetic gastric cancer: muscle-fat ratio from photon-counting CT as a predictor of postoperative complications
Abstract
Background: In diabetic gastric cancer patients, body composition (skeletal muscle–to–fat ratio, MFR) may influence surgical outcomes. We evaluated whether Photon-counting CT (PCD-CT) derived MFR predicts major postoperative complications, reflecting its value in perioperative risk stratification.
Methods: A retrospective analysis of 134 gastric cancer patients with type 2 diabetes was conducted. Preoperative PCD-CT scans assessed body composition. Logistic regression models identified predictors of poor postoperative outcomes, defined by major postoperative complications. The predictive accuracy of models incorporating clinical variables and MFR was evaluated using receiver operating characteristic curves, integrated Discrimination Improvement (IDI), and net Reclassification Improvement (NRI).
Results: Patients who developed major complications (n = 35) had significantly lower skeletal muscle area (45.5 vs. 56.2 cm²; P < 0.01) and higher fat accumulation. Abnormal MFR (0.34–0.57)was a strong predictor of poor outcomes (OR = 1.94, 95% CI: 1.17–2.58, p < 0.01) compared to patients without complications (n = 99). The model combining clinical variables with MFR had the best performance (AUC = 0.75, sensitivity = 0.74, specificity = 0.71) in predicting major complications, outperforming a model based solely on clinical factors. It also showed substantial improvements in predictive accuracy, with an NRI of 0.52 (p < 0.01) and an IDI of 0.09 (p < 0.01).
Conclusion: MFR, quantified by PCD-CT, is a reliable and accurate biomarker for identifying diabetic gastric cancer patients at higher risk of major postoperative complications. MFR demonstrates strong predictive value for adverse surgical outcomes, reinforcing its role in perioperative risk stratification.
Clinical trial number: Not applicable.
Supplementary Information: The online version contains supplementary material available at 10.1186/s12880-025-01872-1.
Keywords: Diabetic; Gastric cancer; Muscle-to‐fat ratio; Photon-counting CT.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This retrospective study was approved by the Human Research Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine (Approval No: IR2024488), adhering to the Declaration of Helsinki. The requirement for informed consent was waived because of the retrospective nature of the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
Optimizing photon counting CT enterography: determining the optimal virtual monoenergy for bowel imaging.Abdom Radiol (NY). 2025 Sep;50(9):3928-3935. doi: 10.1007/s00261-025-04832-z. Epub 2025 Feb 12. Abdom Radiol (NY). 2025. PMID: 39934396
-
Iterative clustering material decomposition aided by empirical spectral correction for photon counting detectors in micro-CT.J Med Imaging (Bellingham). 2024 Dec;11(Suppl 1):S12810. doi: 10.1117/1.JMI.11.S1.S12810. Epub 2024 Dec 27. J Med Imaging (Bellingham). 2024. PMID: 39735346
-
Neurovascular Imaging with Ultra-High-Resolution Photon-Counting CT: Preliminary Findings on Image-Quality Evaluation.AJNR Am J Neuroradiol. 2024 Oct 3;45(10):1450-1457. doi: 10.3174/ajnr.A8350. AJNR Am J Neuroradiol. 2024. PMID: 38760079
-
Cardiac Radiomics Analyses in Times of Photon-counting Computed Tomography for Personalized Risk Stratification in the Present and in the Future.Rofo. 2025 Jul;197(7):781-790. doi: 10.1055/a-2499-3122. Epub 2025 Jan 23. Rofo. 2025. PMID: 39848255 Review. English, German.
-
Postoperative skeletal muscle loss as a prognostic indicator of clinical outcomes in patients with gastric cancer: a systematic review and meta-analysis.J Gastrointest Surg. 2025 Feb;29(2):101898. doi: 10.1016/j.gassur.2024.101898. Epub 2024 Nov 26. J Gastrointest Surg. 2025. PMID: 39608746
References
-
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229–63. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources